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Fraction, volume dose in radiation therapy
Girard, Nicolas Mornex, Francoise 
Centre Hospitalier Lyon Sud, Lyon Pierre Benite, France
Objectives: Discussing how the results of radiotherapy in NSCLC may 
be improved by optimizing fractionation, volume deﬁnition, and total 
doses to the tumor, while preserving the surrounding normal tissues. 
Abstract: Radiotherapy has become a major therapeutic option in tho-
racic oncology. The large accessibility of three-dimensional conformal 
techniques has allowed dose escalation and concurrent combination 
with chemotherapy to occur with acceptable toxicities. Efﬁcacy and 
feasibility of conformal radiotherapy may be improved by a better deﬁ-
nition of the tumor volumes and a ﬁnest focalisation of the ballistics. 
In this way, several issues are currently available, such as optimizing 
fractionation schemes and increasing total doses delivered to the tumor. 
New radiotherapy techniques have been evaluated in prospective 
studies, including respiratory gating, intensity modulation, which may 
allow even superior dose escalation and reduce normal tissues post-ra-
diation complications. In terms of technology, stereotaxic radiotherapy 
and protontherapy, are so far available in a few centers, and represent 
a formidable hope for improved results, especially for early stage lung 
tumors, with preliminary very encouraging results, jeopardizing the use 
of surgery in certain circumstances. These present and future develop-
ments make radiotherapy one of the most promising therapeutics in 
thoracic oncology, and will be presented during the session.
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PS2 patients usually account for a small proportion of patients enrolled 
in trials of ﬁrst-line treatment for advanced disease but represent a sig-
niﬁcantly higher proportion (up to 30%-40%) when population-based 
surveys are conducted . 
As in other types of cancer, PS has a clear prognostic role in advanced 
NSCLC. Median overall survival of patients with PS2, whatever the 
treatment under investigation, is always substantially shorter than that 
of PS0 or PS1 patients, and rarely exceeds 5 months , with 1-year sur-
vival rates <20%. A worse PS is characterised by lower response rates 
to chemotherapy and it is a widely held opinion that these unﬁt patients 
are at higher risk for severe toxicity.
For this sub-group of patients, there is no treatment widely accepted as 
standard and oncologists have to choose among several treatment op-
tions: best supportive care, single-agent chemotherapy, non-platinum-
based combination chemotherapy and platinum-based combination 
chemotherapy.
It is still unclear if the beneﬁt achieved with cisplatin-based chemother-
apy is restricted only to PS0 and PS1 patients, or also applies to PS2 
patients. In the meta-analysis published in 1995, although overall re-
sults were limited by statistical heterogeneity and evident outcome dif-
ferences for the different chemotherapy categories, a signiﬁcant beneﬁt 
was demonstrated for cisplatin-based trials, and a sub-group analysis 
conﬁrmed this beneﬁt for both good and poorer PS patients. However, 
the outcome of 64 PS2 patients enrolled in the clinical trial ECOG 1594 
comparing four platinum-based combinations has proven to be very 
poor. As for the role of carboplatin, the results of the CALGB 9730 
study, comparing paclitaxel plus carboplatin versus paclitaxel alone, 
must be considered. The study enrolled patients with a PS of between 
0 and 2. In the sub-group of PS2 patients median survival in the group 
treated with combination chemotherapy was signiﬁcantly longer than 
with paclitaxel alone. In a randomized phase II study carboplatin plus 
paclitaxel and cisplatin plus gemcitabine, administered at attenuated 
doses, proved to be feasible in PS 2 patients. After 1995, some advan-
tage of chemotherapy versus supportive care alone has been shown 
also with many new cytotoxic agents as gemcitabine, vinorelbine, 
paclitaxel and docetaxel, administered as single agents. These drugs 
are usually characterised by a good tolerability, with a low incidence 
of severe adverse events. Most of the studies show some advantage of 
chemotherapy in terms of overall survival also in the sub-group of PS2 
patients, although formal statistical comparisons are precluded by the 
low absolute number of patients. 
However, there is no consistent evidence that combination chemo-
therapy without platinum is better than third generation drugs given 
as single agents. An Italian randomised trial compared the combina-
tion of gemcitabine and vinorelbine to the two single drugs in patients 
>70 years of age , and the combination did not show advantage over 
mono-chemotherapy in terms of overall survival also in the sub-group 
of PS2 patients. The results of an European Experts Panel on the topic, 
